DDW: Hypnotherapy Effective in Children With Bowel Pain

Make It Routine: Screening for Cognitive Decline in Primary Care

The FDA requires all manufacturers of opioid pain medications to revise labeling to emphasize and explain risks with long-term use.

Anna Chodos, MD, MPH;Sydney Jennings

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.

The Weekly Dose: Insights on Atopic Dermatitis, Menopause Care, Cancer Screening, and Weight Loss Therapy

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

Sydney Jennings

Tirzepatide Proves Noninferiority with Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off

Insights on an FDA-approved multi-cancer detection test, the impact of obesity pharmacotherapy adherence on weight loss outcomes, and more.

Nonmedical Exemptions for Vaccines for Children Should be Eliminated: American Academy of Pediatrics

In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.

Richard Payerchin

FDA Mandates Major Changes to Opioid Labeling

The AAP acknowledges challenges for families but emphasizes mandatory vaccination as crucial for safe school environments.

Related Content

Make It Routine: Screening for Cognitive Decline in Primary Care

The FDA requires all manufacturers of opioid pain medications to revise labeling to emphasize and explain risks with long-term use.

Anna Chodos, MD, MPH;Sydney Jennings

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.

The Weekly Dose: Insights on Atopic Dermatitis, Menopause Care, Cancer Screening, and Weight Loss Therapy

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

Sydney Jennings

Tirzepatide Proves Noninferiority with Dulaglutide for MACE in Lilly's Landmark Incretin Face-Off

Insights on an FDA-approved multi-cancer detection test, the impact of obesity pharmacotherapy adherence on weight loss outcomes, and more.

Nonmedical Exemptions for Vaccines for Children Should be Eliminated: American Academy of Pediatrics

In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.

Richard Payerchin